- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01014156
Epoprostenol in Pulmonary Embolism
Effects of Intravenous Epoprostenol Sodium (Flolan®) in Patients With Moderate-to-Severe Pulmonary Thrombo-Embolism
You are admitted to hospital because of pulmonary embolism. You are treated with anticoagulants.
The investigators know that, despite this treatment, pulmonary embolism can be a threat especially if heart function is compromized.
The investigators investigate a well known study drug (epoprostenol) on top of regular treatment with anticoagulants, to see if heart function can be optimized
Study Overview
Detailed Description
Pulmonary thromboembolism (PE) with circulatory and/or respiratory symptoms is associated with high morbidity and mortality. Acute pulmonary hypertension is the hallmark of severe PE, and is to be held responsible for the full spectrum of clinical manifestations and complications. Although it is common belief that only mechanical obstruction by thrombus mass causes this pulmonary hypertension, there is strong evidence indicating that pulmonary vasoconstriction contributes significantly to the rise in pulmonary vascular resistance.
Although all patients will receive anticoagulant treatment immediately after the diagnosis is established, morbidity and mortality are still disturbingly high when circulatory and/or respiratory symptoms accompany PE, or when hemodynamically stable PE patients have echocardiographic signs of acute right ventricle overload. There are no generally accepted guidelines for additional treatment options in these patients with moderate-to-severe PE. Thrombolytic therapy is recommended by many when hemodynamic symptoms are severe, but its effectiveness has never been proven in a controlled trial. In patients with moderate-to-large PE associated with echocardiographic signs of right ventricle overload, but who are still circulatory stable, mortality is increased, but thrombolytic therapy appears not to be beneficial.
Given the plausible role of pulmonary vasoconstriction in the pathogenesis of PE associated pulmonary hypertension, the potential benefit of pulmonary vasodilators is important.There is experimental evidence that antagonising pulmonary vasoconstriction by the administration of selective vasodilators may be beneficial in animals with PE. In addition, anecdotal evidence of a similar kind exists for humans with acute PE.
We hypothesise that in PE patients who have echocardiographic evidence of acute right ventricle overload, epoprostenol sodium (Flolan®) results in partial or complete reversal of echocardiographic abnormalities, as well as in improvement in respiratory and circulatory symptoms and signs.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Amsterdam, Netherlands, 1081 HV
- Free University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- acute (symptoms <24 hrs) with right ventricular dilatation (>30 mm end diastolic, systolic PAP > 50 mmHg,
- absence of right ventricular wall hypertrophy)
Exclusion Criteria:
- age below 18 years or above 70 years
- body mass index >35 kg/m2
- duration of symptoms >24 hours (since onset or acute increase in symptoms)
- severe circulatory shock (systemic blood pressure systolic <80 mmHg, or diastolic blood pressure <45 mmHg) or respiratory failure, requiring mechanical ventilation.
- patients who, in the opinion of the supervising physician, require thrombolytic therapy.
- severe pre-existent cardiopulmonary disease (heart failure, obstructive pulmonary disease, emphysema)
- atrial fibrillation
- refusal or inability to give informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: epoprostenol intraveneously
epoprostenol iv versus placebo iv, both on top of low molecular weight heparin
|
titration up to 4 ng/kg/min
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Right ventricular end diastolic diameter (ultrasound)
Time Frame: 0, 2,5 4, 24 and 72 hours
|
0, 2,5 4, 24 and 72 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
systolic pulmonary artery pressure (ultrasound)
Time Frame: identical to primary measure
|
identical to primary measure
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 03.123
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Pulmonary Embolism
-
Hospital San Carlos, MadridAsociación de Cardiología Intervencionista de la Sociedad Española de CardiologíaRecruitingPulmonary Embolism | Pulmonary Embolism and Thrombosis | Pulmonary Thromboembolisms | Pulmonary Embolism Acute | Pulmonary Embolism Acute MassiveSpain
-
Inari MedicalCompletedPulmonary Embolism | Submassive Pulmonary Embolism | Acute Pulmonary Embolism | Massive Pulmonary EmbolismUnited States
-
Boston Scientific CorporationEKOS CorporationCompletedPulmonary Embolism | Acute Pulmonary Embolism | Pulmonary Thromboembolism | Massive Pulmonary Embolism | Sub-massive Pulmonary EmbolismUnited States
-
University of California, Los AngelesEnrolling by invitationPulmonary Disease | Pulmonary Embolism | Pulmonary Embolus/Emboli | Pulmonary Embolism and Thrombosis | Pulmonary Embolism Subacute Massive | Pulmonary Embolism Acute MassiveUnited States
-
Imperative Care, Inc.RecruitingCardiovascular Diseases | Vascular Diseases | Embolism | Thrombosis | Thromboembolism | Acute Pulmonary Embolism | Thrombus; Embolism | Emboli, PulmonaryUnited States
-
Akura MedicalNot yet recruiting
-
Nanfang Hospital, Southern Medical UniversityRecruiting
-
Bin HeRecruitingAcute Pulmonary EmbolismChina
-
Angiodynamics, Inc.CompletedPulmonary Embolism | Acute Pulmonary EmbolismUnited States
Clinical Trials on epoprostenol
-
GlaxoSmithKlineCompletedHypertension, PulmonaryUnited States, Netherlands, Canada
-
National Center for Research Resources (NCRR)Baylor College of MedicineCompletedHypertension, Pulmonary
-
ActelionCompletedPulmonary Arterial HypertensionUnited States
-
ActelionCompletedPulmonary Arterial HypertensionUnited States
-
ActelionCompletedPulmonary Arterial HypertensionSpain, Belgium, France, Canada, Italy, Netherlands
-
Aerogen Pharma LimitedCompletedPulmonary HypertensionUnited States
-
Aerogen Pharma LimitedOhio State UniversityCompletedCOVID-19United States
-
Umeå UniversityCompletedTraumatic Brain InjurySweden
-
ActelionChiltern International Ltd.; Effi-StatCompletedPulmonary Arterial HypertensionFrance, Spain, Netherlands, Belgium, Canada, Italy
-
GlaxoSmithKlineCompletedCardiovascular Disease